Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy.

Abstract

INTRODUCTION:

Tropomyosin-related kinase receptor C (TrkC) is a neurotrophin receptor that belongs to the tyrosine kinase receptor family. This family primarily consists of proto-oncogenes, and TrkC has been involved in oncogenic translocations. However, its expression in tumors is often associated with good prognosis, suggesting it actually acts as a tumor suppressor. TrkC has recently been demonstrated to be a dependence receptor, which regulates neuronal survival. Dependence receptors share the ability to trigger apoptosis in the absence of their ligand, a feature that has been suggested to confer a tumor suppressor function to these receptors. A selective advantage for a tumor cell to survive in an environment with limited ligand availability would hence be either to lose the expression of the dependence receptor, or to gain expression of its ligand.

AREAS COVERED:

The role of neurotrophin-3 (NT-3) and its dependence receptor TrkC in neuroblastoma, and its suitability as a therapeutic target.

EXPERT OPINION:

Autocrine production of NT-3 represents a selective advantage for tumor growth and dissemination, in a large fraction of aggressive neuroblastoma. Disruption of the NT-3 autocrine loop in malignant neuroblasts, triggers neuroblastoma cell death, and inhibits neuroblastoma metastasis in animal models. Thus, a novel way of targeting the tyrosine kinase receptor, is via the reactivation of its intrinsic ability to trigger cell death.

• Authors: Servane Tauszig-Delamasure, Jimena Bouzas-Rodriguez
• Journal: Expert opinion on therapeutic targets (Expert Opin Ther Targets) Vol. 15 Issue 7 Pg. 847-58 (Jul 2011) ISSN: 1744-7631 [Electronic] England
• PMID: 21473736 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Neurotrophin 3
• Receptor, trkC

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Child
• Humans
• Neurotrophin 3 (drug effects)
• Oncogenes
• Receptor, trkC (metabolism)